| Literature DB >> 35990786 |
Giada Sebastiani1, Keyur Patel2, Vlad Ratziu3, Jordan J Feld2, Brent A Neuschwander-Tetri4, Massimo Pinzani5, Salvatore Petta6, Annalisa Berzigotti7, Peter Metrakos8, Naglaa Shoukry9, Elizabeth M Brunt10, An Tang11, Jeremy F Cobbold12, Jean-Marie Ekoe13, Karen Seto14, Peter Ghali15, Stéphanie Chevalier16, Quentin M Anstee17, Heather Watson18, Harpreet Bajaj19, James Stone20, Mark G Swain21, Alnoor Ramji22.
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis (NASH). Nearly 25% of patients with NAFLD develop NASH, which can progress to liver cirrhosis and related end-stage complications. Type 2 diabetes and obesity represent the main risk factors for the disease. The Canadian NASH Network is a national collaborative organization of health care professionals and researchers with a primary interest in enhancing understanding, care, education, and research around NAFLD, with a vision of best practices for this disease state. At the 1st International Workshop of the CanNASH network in April 2021, a joint event with the single topic conference of the Canadian Association for the Study of the Liver (CASL), clinicians, epidemiologists, basic scientists, and community members came together to share their work under the theme of NASH. This symposium also marked the initiation of collaborations between Canadian and other key opinion leaders in the field representative of international liver associations. The main objective is to develop a policy framework that outlines specific targets, suggested activities, and evidence-based best practices to guide provincial, territorial, and federal organizations in developing multidisciplinary models of care and strategies to address this epidemic.Entities:
Keywords: Canadian NASH Network; biomedical; clinical; diabetes; epidemiological; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; public health
Year: 2022 PMID: 35990786 PMCID: PMC9231423 DOI: 10.3138/canlivj-2021-0030
Source DB: PubMed Journal: Can Liver J ISSN: 2561-4444